Cardiol Therapeutics Incis A Clinical Stage Life Sciences Company Based In Oakvillecanadadedicated To Developing Therapies For Heart Diseasefounded In 2017The Company Is Publicly Traded On The Nasdaq And Toronto Stock Exchange Under The Ticker Crdlcardiol Focuses On Anti Inflammatory And Anti Fibrotic Treatmentscollaborating With International Researchers And Clinicians To Advance Drug Development The Company S Key Productcardiolrxa Cis A Pharmaceutically Manufactured Cannabidiol Oral Solution Currently In Phase Ii Trials For Acute Myocarditis And Recurrent Pericarditisit Works By Inhibiting The Nlrp3 Inflammasome Pathway To Reduce Inflammation And Fibrosisadditionallycardiol Is Developing Crd 38A Subcutaneous Injection For Heart Failure That Is In Preclinical Developmentcardiol Is Pursuing Fda And Ema Orphan Drug Designations For Cardiolrxa C To Support Its Efforts In Addressing Rare Heart Diseases
